NCT06471088View on ClinicalTrials.gov

Safety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

July 23, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Dovprela

Interventions

DRUG

Dovprela

Daily dose: 200 mg

Trial Locations (1)

Unknown

RECRUITING

Viatris, Seoul

All Listed Sponsors

lead

Viatris Inc.

INDUSTRY